SLC5A2 and heart failure: In a meta-analysis of randomized controlled trials (RCTs) without Dapagliflozin Evaluation to Improve the LIVEs of Patients With PReserved Ejection Fraction Heart Failure (DELIVER), the beneficial effects of SGLT2 inhibitors were found to reduce cardiovascular mortality and hospitalization for heart failure, but not overall mortality in patients with HFpEF [17].